These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9014749)

  • 41. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?
    McMahon N; Cheng TY; Beasley GM; Spasojevic I; Petros W; Augustine CK; Zipfel P; Padussis JC; Sanders G; Tyler DS
    Ann Surg Oncol; 2009 Apr; 16(4):953-61. PubMed ID: 19184236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.
    Muilenburg DJ; Beasley GM; Thompson ZJ; Lee JH; Tyler DS; Zager JS
    Ann Surg Oncol; 2015 Feb; 22(2):482-8. PubMed ID: 25192683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Four times repeated isolated limb infusion with melphalan-controlled locoregional disease in the patient with melanoma of the leg.
    El Halabi H; Hijaz F; Gushchin V
    Am Surg; 2012 Dec; 78(12):E504-5. PubMed ID: 23265100
    [No Abstract]   [Full Text] [Related]  

  • 44. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials.
    Lens MB; Dawes M
    Lancet Oncol; 2003 Jun; 4(6):359-64. PubMed ID: 12788409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model.
    Wu Z; Roberts MS; Parsons PG; Smithers BM
    Melanoma Res; 1997 Feb; 7(1):19-26. PubMed ID: 9067961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma.
    Hafström L; Hugander A; Jönsson PE; Westling H; Ehrsson H
    Cancer Treat Rep; 1984 Jun; 68(6):867-72. PubMed ID: 6733699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective therapy: repeat limb perfusion for recurrent melanoma.
    Krementz ET
    J Am Coll Surg; 1996 Jun; 182(6):547-8. PubMed ID: 8646356
    [No Abstract]   [Full Text] [Related]  

  • 48. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
    Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-centre prospective study of isolated limb perfusion with melphalan in the treatment of subungual malignant melanoma.
    Lingam MK; McKay AJ; Mackie RM; Aitchison T
    Br J Surg; 1995 Oct; 82(10):1343-5. PubMed ID: 7489159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Future directions in regional treatment strategies for melanoma and sarcoma.
    Beasley GM; Ross MI; Tyler DS
    Int J Hyperthermia; 2008 May; 24(3):301-9. PubMed ID: 18393007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Isolated limb perfusion for malignant melanoma; possibly better results with high dose hyperthermia.
    Van der Zee J; Kroon BB
    Int J Hyperthermia; 2008 Nov; 24(7):602-3; author reply 604. PubMed ID: 18979311
    [No Abstract]   [Full Text] [Related]  

  • 53. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
    Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
    Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
    Grünhagen DJ; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg; 2004 Dec; 240(6):939-47; discussion 947-8. PubMed ID: 15570199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.
    Kroon HM; Huismans AM; Kam PC; Thompson JF
    J Surg Oncol; 2014 Mar; 109(4):348-51. PubMed ID: 24522939
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isolated hyperthermic limb perfusion chemotherapy in Merkel cell tumour: a case report.
    Dawson R; Williams OM; Mansel RE
    J R Coll Surg Edinb; 1996 Aug; 41(4):255-6. PubMed ID: 8772077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
    Beasley GM; McMahon N; Sanders G; Augustine CK; Selim MA; Peterson B; Norris R; Peters WP; Ross MI; Tyler DS
    Cancer; 2009 Oct; 115(20):4766-74. PubMed ID: 19637344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.